Source comparison
Limitations of This Comparison
Several structural limitations constrain everything above, and honest readers should keep them in view: No head-to-head data. Comparing the two requires stitching together unrelated studies of different molecules, endpoints, and settings — a chain with several
This comparison does not assign a generated winner or score.
- Several structural limitations constrain everything above, and honest readers should keep them in view:
- No head-to-head data. Comparing the two requires stitching together unrelated studies of different molecules, endpoints, and settings — a chain with several weak links.
- Asymmetric literature. One compound has controlled trials; the other has case reports. That is not a like-for-like evidence comparison, and the asymmetry itself is the finding.
- Approved drug ≠ research powder. Afamelanotide’s trial data describe a characterized implant delivered by clinicians — not a self-injected research vial of a Melanotan-1 peptide, and certainly not Melanotan 2.
- Case-report bias. Harm reports document what was noticed and published; they cannot establish incidence, causation, or safe use.
- Research-chemical identity. Gray-market Melanotan 2 is of unverified identity, purity, and sterility; trial or label data never describe what is actually in such a vial.